CBR-096-4

• Description:

  CBR-096-4 is a derivative of Itraconazole (HY-17514) . CBR-096-4 is an orally active antifibrotic agent with no CYP3A4 inhibitory activity. CBR-096-4 inhibits the formation of matrix-secreting activated myofibroblasts (MFBs) from multiple tissue types. CBR-096-4 inhibits Hedgehog reporter activity (GLI-LUC), VEGF-dependent growth, and αSMA-LUC reporter activity. CBR-096-4 can be used for research of fibrosis[1].

• UNSPSC:

  12352005

• Target:

  Hedgehog

• Related Pathways:

  Stem Cell/Wnt

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C1N(C(C)CC)N=CN1C2=CC=C(N3CCN(C4=CC=C(OC[C@@H]5O[C@](C6=CC=CC=C6)(CN7N=CC=N7)OC5)C=C4)CC3)C=C2

• Molecular Formula:

  C35H40N8O4

• Molecular Weight:

  636.74

• References & Citations:

  [1]Bollong MJ, et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc Natl Acad Sci U S A. 2017 May 2;114 (18) :4679-4684.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1776931-05-5]